Keros Therapeutics, Inc. (KROS) Aandelenanalyse

Bedrijfsoverzicht

Keros Therapeutics, Inc. is a clinical-stage biopharmaceutical entity dedicated to the development and commercialization of novel therapeutics designed to treat patients suffering from disorders linked to the dysfunctional signaling of the transforming growth factor-beta family of proteins within the United States market. This specialized focus positions the company squarely within the Healthcare sector and the Biotechnology industry, sectors characterized by high research and development intensity and significant regulatory hurdles that define the competitive landscape for innovative drug candidates. The firm operates with a workforce of 78 employees, supporting its valuation as a mid-cap entity with a market capitalization of $341.37 million and a trailing twelve-month revenue base of $244.06 million. These financial metrics indicate that while the company has achieved substantial revenue generation relative to its small headcount, its market valuation reflects the premium investors place on clinical-stage assets, yet the revenue scale suggests the company has moved beyond the typical early-stage venture capital phase into a period of more established commercial activity.

Financiële gezondheid

The company reported a trailing twelve-month revenue of $244.06 million and a corresponding net income of $87.01 million, supported by an EBITDA figure of $72.08 million. The significant disparity between the gross revenue figure and the net income reveals a complex cost structure where non-operating expenses or specific accounting adjustments have impacted the bottom line, as the net income percentage is notably higher than the profit margin would typically suggest given the operating context. Keros Therapeutics generated $66.24 million in free cash flow, which provides the organization with substantial financial flexibility to fund ongoing clinical trials, expand manufacturing capabilities, or pursue strategic acquisitions without immediate reliance on external capital markets. The margin profile presents a distinct divergence: the gross margin stands at 47.9%, indicating healthy pricing power or cost control on product sales, while the operating margin is reported as -7576.6%, suggesting significant non-recurring costs or specific accounting classifications, contrasted against a profit margin of 35.7% which reflects the final net income relative to revenue. The balance sheet demonstrates a conservative stance with total cash holdings of $287.42 million significantly exceeding total debt obligations of $16.88 million, a situation further underscored by a debt-to-equity ratio of 5.57 which, despite the high numerical value, is mitigated by the massive cash buffer preventing a distressed leverage profile. Liquidity is exceptionally strong as evidenced by a current ratio of 15.45, indicating that the company possesses more than fifteen times the current assets necessary to cover its short-term liabilities. Efficiency in capital deployment is highlighted by a return on equity of 19.9% and a return on assets of 9.2%, metrics that reveal management's effectiveness in generating returns from the shareholder equity and the total asset base respectively.

Waarderingsbeoordeling

Valuation multiples for Keros Therapeutics show a trailing P/E ratio of 4.87 and a forward P/E of -2.22, a discrepancy that implies the market anticipates a shift in earnings trajectory or that forward projections incorporate significant expected losses or adjustments not yet reflected in current earnings. The price-to-book ratio is recorded at 0.72, indicating that the stock is trading below its book value, which often signals either a market undervaluation of the company's assets or expectations that future earnings will struggle to materialize at current valuations. Alternative valuation metrics such as the price-to-sales ratio of 1.40 and the EV/EBITDA of -0.69 suggest that traditional earnings-based comparisons are less relevant, and investors are likely pricing the stock based on revenue growth potential or asset quality rather than current profitability. The 52-week trading range spans from a low of $10.41 to a high of $22.55, providing a clear band of historical volatility within which the current price must be evaluated to determine if the stock is approaching resistance levels or near support zones. The beta coefficient is 0.99, which indicates that the stock's price volatility has historically moved in tandem with the broader market, suggesting that systematic risk exposure is neutral rather than amplified or dampened relative to the S&P 500.

Growth & Income

The revenue growth year-over-year is reported at -87.3%, while earnings growth is listed as N/A, indicating that the company is currently experiencing a contraction in top-line sales or a reclassification of revenue streams rather than organic expansion. This contraction in revenue growth suggests that the company is either in a transitional phase of product lifecycle management or facing specific market headwinds that are impacting the commercialization of its therapeutic portfolio more aggressively than its earnings metrics currently reflect. Regarding income distribution, the company does not pay a dividend, evidenced by a dividend yield of N/A and a payout ratio of 0.0%, which means the firm retains all its earnings and reinvests them directly back into research and development to sustain its clinical-stage pipeline. Consequently, the overall growth and income profile of Keros Therapeutics is defined by a lack of current income generation for shareholders, relying instead on the potential for future value creation through the successful commercialization of its novel therapeutics and the resolution of the current revenue contraction.